搜尋
RAPT Therapeutics Inc
RAPT添加自選
58.020USD
0.0000.00%
收盤 05/13, 16:00（美東）報價延遲15分鐘
1.68B總市值
虧損本益比TTM
關於 RAPT Therapeutics Inc 公司
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
RAPT Therapeutics Inc簡介
公司代碼RAPT
公司名稱RAPT Therapeutics Inc
上市日期Oct 31, 2019
CEOWong (Brian)
員工數量68
證券類型Ordinary Share
年結日Oct 31
公司地址561 Eccles Ave
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94080
電話16504899000
網址https://rapt.com/
公司代碼RAPT
上市日期Oct 31, 2019
CEOWong (Brian)
RAPT Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
-100.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 5月10日 週日
更新時間: 5月10日 週日
持股股東
股東類型
持股股東
持股股東
佔比
TCG Crossover Management, LLC
8.92%
Forbion Capital Partners
6.33%
OrbiMed Advisors, LLC
5.67%
RTW Investments L.P.
5.65%
Foresite Capital Management, LLC
5.40%
其他
68.03%
持股股東
持股股東
佔比
TCG Crossover Management, LLC
8.92%
Forbion Capital Partners
6.33%
OrbiMed Advisors, LLC
5.67%
RTW Investments L.P.
5.65%
Foresite Capital Management, LLC
5.40%
其他
68.03%
股東類型
持股股東
佔比
Hedge Fund
31.95%
Investment Advisor
21.24%
Investment Advisor/Hedge Fund
17.42%
Private Equity
17.32%
Venture Capital
6.93%
Research Firm
1.62%
Individual Investor
0.24%
Pension Fund
0.07%
Bank and Trust
0.06%
其他
3.15%
機構持股
更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
301
29.16M
100.68%
+8.21M
2025Q4
290
18.77M
64.82%
+126.40K
2025Q3
290
16.78M
61.62%
-1.23M
2025Q2
295
16.40M
99.19%
-1.13M
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
TCG Crossover Management, LLC
1.64M
5.9%
--
--
Sep 30, 2025
Forbion Capital Partners
1.83M
6.62%
+1.49M
+432.58%
Oct 23, 2025
OrbiMed Advisors, LLC
1.09M
3.92%
-555.29K
-33.82%
Sep 30, 2025
RTW Investments L.P.
1.47M
5.31%
--
--
Sep 30, 2025
Foresite Capital Management, LLC
1.56M
5.64%
--
--
Sep 30, 2025
Invus Public Equities Advisors, LLC
580.47K
2.09%
+580.47K
--
Sep 30, 2025
Frazier Life Sciences Management, L.P.
983.33K
3.4%
+983.33K
--
Dec 31, 2025
Braidwell LP
929.69K
3.21%
+929.69K
--
Dec 31, 2025
Redmile Group, LLC
552.59K
1.99%
-78.09K
-12.38%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Invesco Dorsey Wright SmallCap Momentum ETF
0.56%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Blueprint Chesapeake Multi-Asset Trend ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 3000 ETF
0%
Pacer WealthShield ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
查看更多
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.56%
Avantis US Small Cap Equity ETF
佔比0.02%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Schwab U.S. Broad Market ETF
佔比0%
Blueprint Chesapeake Multi-Asset Trend ETF
佔比0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
Pacer WealthShield ETF
佔比0%
T Rowe Price Small-Mid Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
Jun 13, 2025
Merger
8→1
公告日期
除權除息日
類型
比率
Jun 13, 2025
Merger
8→1
